

CBE ID

0220

Title

Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB - Stage III hormone receptor positive breast cancer

Endorsement Status

Endorsed

Is Under Review

No

Next Maintenance Cycle

Fall 2026

Previous Endorsement Cycle

Fall 2019

Initial Endorsement

Wed, 02/28/2007 - 19:00

Steward

American College of Surgeons

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Percentage of female patients, age = 18 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC T1cN0M0 or stage IB to IIIC, whose primary tumor is of the breast, and is progesterone or estrogen receptor positive with adjuvant hormonal therapy (recommended or administered) within 1 year (365 days) of diagnosis

1.7 Measure Type

Process

1.8 Level of Analysis

Facility

1.13 Data Dictionary

Not attached. I attest that all information will be provided where codes and/or value sets are needed (1.14a - 1.15c).

1.14 Numerator

Adjuvant hormonal therapy is administered within 1 year (365 days) of the date of diagnosis or it is recommended but not administered

1.15 Denominator

Include if all of the following characteristics are identified: WomenAge = 18 at time of diagnosisKnown or assumed to be first or only cancer diagnosisEpithelial malignancy onlyInvasive tumorsPrimary tumors of the breastAJCC T1cN0M0 or Stage IB - IIIC Primary tumor is estrogen receptor positive or progesterone receptor positiveAll or part of 1st course of treatment performed at the reporting facilityKnown to be alive within 1 year (365 days) of date of diagnosisSurgical procedure of the primary site

6.1.2 Current or Planned Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Public Reporting, Regulatory and Accreditation Programs, Quality Improvement (Internal to the specific organization)

Exclusions

Exclude, if any of the following characteristics are identified:

Men

Under age 18 at time of diagnosis

Second or subsequent cancer diagnosis

Tumor not originating in the breast

Non-epithelial malignancies, exclude malignant phyllodes tumors; 8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 - Carcinosarcoma; 8981 - Carcinosarcoma, embryonal

Non-invasive tumors

Stage 0, in-situ tumor

Stage IV, metastatic tumor

Primary tumor is estrogen receptor negative and progesterone receptor negative

None of 1st course therapy performed at reporting facility

Died within 1 year (365 days) of diagnosis,

Patient enrolled in a clinical trial that directly impacts delivery of the standard of care

No surgical procedure of the primary site

Not AJCC T1cN0M0 or not AJCC stage IB-IIIC

Risk Adjustment

No risk adjustment or risk stratification

Target Population

Elderly

Use In Federal Program

Hospital Compare, Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting

The measure developer is different from the measure steward

No

Steward Organization

American College of Surgeons

Steward POC email

bpalis@facs.org